Shifeng Pan Ph.D.
CSO
Shifeng brings to Genesis more than two decades of experience in drug discovery across multiple therapeutic areas, which includes a 22-year career at Novartis, where he served as the Head of Discovery Chemistry at the Genomics Institute of the Novartis Research Foundation. There, he led the discovery of FDA-approved drugs ODOMZO®, BRAFTOVI®, and MAYZENT®, as well as numerous other programs across several therapeutic areas. Shifeng comes to Genesis from Odyssey Therapeutics, where he was Executive Vice President and Head of Discovery. He holds a Ph.D. in organic chemistry from New York University.
In the News
We are proud to enable the broader ML research ecosystem through publications and open-source contributions, academic collaborations, and conference sponsorships.
